• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Stroke prevention in atrial fibrillation: Closing the gap
Publication date: Available online 25 October 2018Source: American Heart JournalAuthor(s): Sean D. Pokorney, Bernard J. Gersh, Azhar Ahmad, Sana M. Al-Khatib, Melanie Blank, Megan Coylewright, Peter DiBattiste, Jeff S. Healey, Olaf Hedrich, Elaine M. Hylek, Eva Kline-Rogers, Eric D. Peterson, Phil Mendys, Michael J. Mirro, Gerald Naccarelli, Parashar Patel, Christian T. Ruff, Howard Rutman, Norman Stockbridge, Robert Temple
Source: American Heart Journal - October 25, 2018 Category: Cardiology Source Type: research

Outcomes of Apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial
ConclusionsMulti-morbidity is prevalent among the population with AF; efficacy and safety of apixaban is preserved in this subgroup supporting extension of trial results to the most complex AF patients.Clinical trial registrationClinicalTrials.gov (NCT00412984).
Source: American Heart Journal - November 23, 2018 Category: Cardiology Source Type: research

Design and rationale of a pragmatic trial integrating routine screening for atrial fibrillation at primary care visits: The VITAL-AF trial
Publication date: Available online 22 June 2019Source: American Heart JournalAuthor(s): Jeffrey M. Ashburner, Steven J. Atlas, David D. McManus, Yuchiao Chang, Ana T. Trisini Lipsanopoulos, Leila H. Borowsky, Wyliena Guan, Wei He, Patrick T. Ellinor, Daniel E. Singer, Steven A. LubitzAbstractGiven the preventable morbidity and mortality associated with atrial fibrillation (AF), increased awareness of undiagnosed AF, and advances in mobile ECG technology, there is a critical need to assess the effectiveness of using such technology to routinely screen for AF in clinical practice. VITAL-AF is a pragmatic trial that will test...
Source: American Heart Journal - June 24, 2019 Category: Cardiology Source Type: research

Incidence and predictors of atrial fibrillation episodes as detected by implantable loop recorder in patients at risk From the LOOP study
ConclusionA considerable burden of previously unknown AF was detected when long-term monitoring was applied in at-risk patients. Biomarkers were associated with AF incidence and improved prediction of long AF episodes.
Source: American Heart Journal - October 21, 2019 Category: Cardiology Source Type: research

Sex-specific Cardiac Phenotype and Clinical Outcomes in Patients with Hypertrophic Cardiomyopathy
ConclusionsOur results suggest that sex-specific differences in LV geometry, hyper-contractility and diastolic function, not greater degree of LV myopathy, contribute to a higher, age-independent risk of diastolic HF in women with HCM.Graphical abstract
Source: American Heart Journal - October 21, 2019 Category: Cardiology Source Type: research

Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation
ConclusionsIn AF patients, there is underuse of GDT for non-AF comorbidities. The association between GDT use and outcomes was strongest in heart failure and obstructive sleep apnea patients where use of GDT was associated with lower mortality and less AF progression.
Source: American Heart Journal - November 9, 2019 Category: Cardiology Source Type: research

Comparison of expected and observed outcomes for septal myectomy in hypertrophic obstructive cardiomyopathy
ConclusionsSeptal myectomy, performed in a tertiary referral center, had a 30-day mortality rate of 0% and low morbidity rate. There was no difference between observed myectomy mortality and STS Calculator predicted risk for AVR and MV repair. It is possible that a larger sample could reveal lower mortality than STS prediction.
Source: American Heart Journal - December 19, 2019 Category: Cardiology Source Type: research

Rivaroxaban versus warfarin in patients with non-valvular atrial fibrillation and stage IV-V chronic kidney disease
ConclusionsNo statistically significant difference in the risk of ISSE or major bleeding was found between rivaroxaban- and warfarin-treated patients. While further study is needed, rivaroxaban appears to be a reasonable alternative to warfarin for ISSE prevention in the setting of NVAF and stage IV-V CKD.
Source: American Heart Journal - January 22, 2020 Category: Cardiology Source Type: research

Association of Postoperative Complications and Outcomes Following Coronary Artery Bypass Grafting
ConclusionsPostoperative complications are associated with an increased risk of both early and late mortality and all-cause rehospitalization, particularly during the “value” window within 90 days of CABG. These findings underscore the need to develop avoidance strategies as well as cost-adjustment methods for each of these complications.
Source: American Heart Journal - February 9, 2020 Category: Cardiology Source Type: research

Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk
Publication date: Available online 19 August 2020Source: American Heart JournalAuthor(s): Hiroshi Kawakami, Mark T. Nolan, Karen Phillips, Paul A Scuffham, Thomas H. Marwick
Source: American Heart Journal - August 19, 2020 Category: Cardiology Source Type: research

Edoxaban versus Warfarin in Patients with Atrial Fibrillation in Relation to the Risk of Stroke: A Secondary Analysis of the ENGAGE AF-TIMI 48 Study
Publication date: Available online 22 January 2021Source: American Heart JournalAuthor(s): Joris R. de Groot, Christian T. Ruff, Sabina A. Murphy, Rose A. Hamershock, Jim T. Vehmeijer, Anton J.M. Oude Ophuis, Laura Grip, Hans Lanz, Michele F. Mercuri, Elliott M. Antman, RobertP. Giugliano
Source: American Heart Journal - January 23, 2021 Category: Cardiology Source Type: research

Periodontal Disease, Atrial Fibrillation and Stroke
Publication date: Available online 24 January 2021Source: American Heart JournalAuthor(s): Souvik Sen, Kolby Redd, Tushar Trivedi, Kevin Moss, Alvaro Alonso, Elsayed Z. Soliman, Jared W. Magnani, Lin Y. Chen, Rebecca F. Gottesman, Wayne Rosamond, James Beck, Stephen Offenbacher
Source: American Heart Journal - January 25, 2021 Category: Cardiology Source Type: research

Rivaroxaban Monotherapy versus Combination Therapy According to Patient Risk of Stroke and Bleeding in Atrial Fibrillation and Stable Coronary Disease: AFIRE trial sub-analysis
Publication date: Available online 28 February 2021Source: American Heart JournalAuthor(s): Masaharu Akao, Satoshi Yasuda, Koichi Kaikita, Junya Ako, Tetsuya Matoba, Masato Nakamura, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Kunihiko Matsui, Hisao Ogawa
Source: American Heart Journal - March 1, 2021 Category: Cardiology Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11